Sentences with phrase «investigators at the cancer»

In a previous study, investigators at the Cancer Institute showed that using a vaccine treatment for bladder and breast cancer tumors in laboratory models resulted in a reversal of the traditional immune blockade, as well as the development of tumor specific immunity throughout the body.

«Salmonella strains have a natural preference for infiltrating and replicating within the cancer cells of a tumor, making the bacteria an ideal candidate for bacteriotherapy,» said Robert Kazmierczak, a senior investigator at the Cancer Research Center and a post-doctoral fellow in the Division of Biological Sciences in the MU College of Arts and Science.

Not exact matches

At UW he founded the Center for Cancer Innovation, which brings together a distributed network of investigators to help patients with advanced cCancer Innovation, which brings together a distributed network of investigators to help patients with advanced cancercancer.

The Pershing Square Sohn Prize for Young Investigators in Cancer Research will provide young New York - based scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking.

Dr. Fong is also the site principal investigator at UCSF for the NCI - sponsored Cancer Immunotherapy Trials Network (CITN).

«Our study shows that epigenetic drift, which is characterized by gains and losses in DNA methylation in the genome over time, occurs more rapidly in mice than in monkeys and more rapidly in monkeys than in humans,» explains Jean - Pierre Issa, MD, Director of the Fels Institute for Cancer Research at LKSOM, and senior investigator on the new study.

«We know about the dose - limiting side - effects of liposomes, but no one had looked at what happens to the liposome over time in the skin — how they get there and what happens to liposomes after injection,» says Dmitri Simberg, PhD, investigator at the CU Cancer Center and the paper's senior author.

To determine whether this long held belief is true, investigators from John Wayne Cancer Institute utilized their institution's melanoma database to analyze data on 2,025 women age 18 to 50 diagnosed with stage I to IV melanoma who were treated at their institution between 1971 and 2016.

This is the main finding of new research led by investigators at NYU Langone Medical Center and its Perlmutter Cancer Center and published online May 19 in the Journal of the National Cancer Institute.

The protein puts the immune system's brakes on, keeping its T cells from recognizing and attacking cancer cells, said Dr. Antoni Ribas, the study's principal investigator and a professor of medicine in the division of hematology - oncology at the David Geffen School of Medicine at UCLA.

«It's not clear whether there are signals controlling this or whether it's just random,» says principal investigator Jonas Fuxe, cancer researcher and Associate Professor at Karolinska Institutet's Department of Medical Biochemistry and Biophysics.

The study of 1,003 men was conducted at the NIH in Bethesda, Md., from 2007 - 2014, with Peter A. Pinto, MD, the head of the prostate cancer section of the urologic oncology branch, serving as the senior investigator.

«These are optimistic results for one of the first targeted therapies for cancer stem cells,» says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer Centercancer stem cells,» says Antonio Jimeno, MD, PhD, investigator at the CU Cancer Center, director of the university's Cancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer CenterCancer Center, director of the university's Cancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer CenterCancer Stem Cell - Directed Clinical Trials Program, and principal investigator of the clinical trial at the CU Cancer CenterCancer Center site.

Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment - resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh Cancer Institute (UPCI).

«The results of the phase III clinical trial show that a target fusion biopsy detects more clinically significant prostate cancer,» said Art Rastinehad, DO, principal investigator of the study and director of interventonal urologic oncology at North Shore - LIJ's Arthur Smith Institute for Urology, in New Hyde Park, NY.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

Reviewing thousands of genome wide associate studies (GWAS) to identify genetic variants in single nucleotide polymorphisms (SNPs), investigators at Dartmouth's Norris Cotton Cancer Center found that some alleles (one of a pair of genes located on a specific chromosome) are more frequently risk - associated with disease than protective.

The study was led by Dr. Alexandre Zlotta, Director of Uro - Oncology at Mount Sinai Hospital, and researcher with the Lunenfeld - Tanenbaum Research Institute, part of Sinai Health System in Toronto, Canada, and Dr. Paul Boutros, Principal Investigator, Informatics and Bio-computing, Ontario Institute for Cancer Research (OICR).

UTSW co-authors include: Co-lead author Maria Winter, a research associate; Dr. Luisella Spiga, a postdoctoral researcher; visiting fellow Lisa Büttner; graduate students Elizabeth Hughes and Caroline Gillis, all of Microbiology; Dr. Breck Duerkop, Instructor, Immunology; Cassie Behrendt, a research technician, Immunology; Dr. Lora Hooper, Professor and Chair of Immunology with appointments in Microbiology and in the Center for the Genetics of Host Defense, a HHMI Investigator and holder of the Jonathan W. Uhr, M.D. Distinguished Chair in Immunology, and the Nancy Cain and Jeffrey A. Marcus Scholar in Medical Research, in Honor of Dr. Bill S. Vowell; Dr. Luis Sifuentes - Dominguez, Instructor of Pediatrics; Dr. Kayci Huff - Hardy, clinical fellow, Internal Medicine in the Division of Digestive and Liver Diseases; Dr. Andrew Koh, Associate Professor of Pediatrics and Microbiology and in the Harold C. Simmons Comprehensive Cancer Center as well as Director of Pediatric Hematopoietic Stem Cell Transplantation at Children's Health; and Dr. Ezra Burstein, Professor of Internal Medicine and Molecular Biology and Chief of the Division of Digestive and Liver Diseases.

«Sometimes postdocs lose motivation if they feel that the project is not theirs,» says Ana Gamero, principal investigator at the National Cancer Institute in Frederick, Maryland.

It's time for the Surgeon General to say the same thing about UV tanning,» says Robert P. Dellavalle, MD, PhD, MSPH, investigator at the CU Cancer Center, associate professor of dermatology at the University of Colorado School of Medicine, and the study's senior author.

The investigators looked at 4,278 tumor samples from a tissue repository of patients with GI tract cancers.

«This is a step forward in understanding pancreatic cancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer Ccancer's resistance to standard therapies,» said principal investigator Gregory Beatty, MD, PhD, an assistant professor of Hematology / Oncology at Penn and a member of Penn's Abramson Cancer CCancer Center.

The team of investigators from Memorial Sloan Kettering Cancer Center, New York City, analyzed data from the National Cancer Data Base (NCDB) of the American College of Surgeons and the American Cancer Society, and looked at more than 1 million women who underwent mastectomy due to breast cancer between 1998 andCancer Center, New York City, analyzed data from the National Cancer Data Base (NCDB) of the American College of Surgeons and the American Cancer Society, and looked at more than 1 million women who underwent mastectomy due to breast cancer between 1998 andCancer Data Base (NCDB) of the American College of Surgeons and the American Cancer Society, and looked at more than 1 million women who underwent mastectomy due to breast cancer between 1998 andCancer Society, and looked at more than 1 million women who underwent mastectomy due to breast cancer between 1998 andcancer between 1998 and 2011.

Today, a team of researchers at Cold Spring Harbor Laboratory reports in the journal Genes & Development that they have arrived at «new insights into signaling events that underlie metastasis in ovarian cancer cells,» says Gaofeng Fan, Ph.D., postdoctoral investigator who conducted most of the experiments, in the laboratory of his mentor, CSHL Professor Nicholas K. Tonks.

Circulating tumor cell (CTC) clusters — clumps of from 2 to 50 tumor cells that break off a primary tumor and are carried through the bloodstream — appear to be much more likely to cause metastasis than are single CTCs, according to a study from investigators at the Massachusetts General Hospital (MGH) Cancer Center.

They also fail to emphasize healthy menu items, investigators at Dartmouth - Hitchcock's Norris Cotton Cancer Center have found.

The «payline,» or success rate, for bread - and - butter investigator grants (R01s) at the National Cancer Institute (NCI) this year, after peer approval, will drop to 11 %, compared to 22 % 4 years ago.

«The PSA test is based on the fact that men with higher levels of the PSA protein are more likely to have prostate cancer,» said William Catalona, MD, principal investigator on the Prostate Health Index clinical study and urologist at Northwestern Medicine and director of the Clinical Prostate Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in Febcancer,» said William Catalona, MD, principal investigator on the Prostate Health Index clinical study and urologist at Northwestern Medicine and director of the Clinical Prostate Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in FebCancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, where they began using the phi test on patients in FebCancer Center of Northwestern University, where they began using the phi test on patients in February.

The first large U.S. study aimed at resolving an ongoing debate about the best way to treat an early sign of breast cancer will launch later this year under the direction of a Duke Cancer Institute investicancer will launch later this year under the direction of a Duke Cancer Institute investiCancer Institute investigator.

Principal investigator Leena Gandhi, MD, PhD, director of the thoracic medical oncology program at Perlmutter Cancer Center at NYU Langone Health and associate professor of Medicine in the division of Medical Oncology at NYU School of Medicine, presented these findings April 16 at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago.

«Our data strongly suggest that KIF1Bβ, which is localized on chromosome 1p36, might be such a neuroblastoma tumor suppressor gene,» says principal investigator Susanne Schlisio at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet and Assistant Member at the Ludwig Institute for Cancer Research in Stockholm, Sweden.

These results are among the best in the field, offering a lot of hope to people with ALK - positive lung cancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investicancer,» says D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado Cancer Center and the trial's principal investiCancer Center and the trial's principal investigator.

«Breast cancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer Ccancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer CCancer Center.

«The findings of both studies support a growing body of research that suggests lifestyle interventions lower biomarkers associated with breast cancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stcancer recurrence and mortality, and improve quality of life,» said Melinda Irwin, PhD, co-program leader of the Cancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Prevention and Control Research Program at Yale Cancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both stCancer Center, associate professor of Epidemiology at Yale School of Public Health, and principal investigator on both studies.

García - Añoveros also is an investigator at Northwestern's Knowles Hearing Center and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Principal investigator E. Shelley Hwang, M.D., chief of breast surgery at the Duke Cancer Institute and vice chair of research in the Duke University Department of Surgery, will lead the study through the cooperative group, The Alliance for Clinical Trials in Oncology.

Nevertheless, we are rapidly translating this discovery for use in the clinic,» says the study's senior investigator, Stephen Byers, PhD, a professor and molecular oncologist at Georgetown Lombardi Comprehensive Cancer Center, a part of GUMC.

The senior author of the study, Deanna Kepka, PhD, MPH, a Huntsman Cancer Institute investigator and assistant professor in the College of Nursing at the University of Utah, added that, «We are interested in looking at cultural values that may make certain demographic groups in the United States, such as Latinos, more supportive of adolescent vaccination than other demographic groups.

«The model allowed us to ask what would have been the right drug in each case, how could we have known from the tumor's genetics, and what difference it made,» says Jennifer R. Diamond, MD, CU Cancer Center investigator and medical oncologist at the University of Colorado Hospital.

A phase I clinical trial conducted by investigators at the University of Texas San Antonio, showed that the combination of HCQ and the chemotherapy drug vorinostat in 27 patients with advanced solid tumors, including renal cell carcinoma and colon cancer, was clinically safe and inhibited autophagy.

«The biggest issue will be price,» says John Schiller, a senior investigator at the National Cancer Institute, who did some of the early work that led to the vaccine's development.

«This study defines a signaling axis that is essential for head and neck cancer progression, and our findings show that this axis may be disrupted at three key steps,» says principal investigator Quintin Pan, PhD, associate professor of otolaryngology at the OSUCCC — James.

A team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has now identified and validated an accurate 5 - gene classifier for discriminating early pancreatic cancer from non-malignant tissue.

In the new study of 8,000 cancer cases, the investigators focused on mutations involving letters that are inserted at the same time that other letters are deleted.

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

Sylvia Adams, MD, associate professor of medical oncology at Perlmutter Cancer Center and principal investigator of this study, presented the findings on June 3 in Chicago at the annual meeting of the American Society of Clinical Oncology.

Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program for the CCC, co-leader of the UC Cancer Institute's Comprehensive Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown promise for causing immune responses against tumor antigens to improve patient outcomes.

A new study from Sidney Kimmel Cancer Center (SKCC) at Thomas Jefferson University investigator Christine Eischen, PhD, provides new insights into the mechanisms contributing to ovarian cCancer Center (SKCC) at Thomas Jefferson University investigator Christine Eischen, PhD, provides new insights into the mechanisms contributing to ovarian cancercancer.

«For someone to go up against alectinib, it would be nice to know earlier if there might be an improvement,» says Robert C. Doebele, MD, PhD, investigator at the University of Colorado Cancer Center and associate professor of Medical Oncology at the CU School of Medicine.